Skip to main
AMGN

Amgen (AMGN) Stock Forecast & Price Target

Amgen (AMGN) Analyst Ratings

Based on 18 analyst ratings
Hold
Strong Buy 11%
Buy 17%
Hold 67%
Sell 6%
Strong Sell 0%

Bulls say

Amgen is a leader in biotechnology-based human therapeutics, with a strong portfolio of flagship drugs including Epogen, Aranesp, Neupogen, Neulasta, Enbrel, and Otezla. Recent launches, such as Repatha, Aimovig, Lumakras, and Tezspire, have bolstered the company's offerings. The acquisition of Onyx Pharmaceuticals and 2023 Horizon has also added a diverse range of rare-disease drugs. Positive trends in key metrics, such as Repatha's growing total and new prescriptions, and the potential of Tepezza's self-administered option could further boost Amgen's growth potential.

Bears say

Amgen is facing headwinds in 2026 due to biosimilar/generic competition and weak script trends for Prolia, Xgeva, and Otezla. However, with the anticipated label expansion for Tezspire in chronic rhinosinusitis with nasal polyps and potential for growth in eosinophilic esophagitis and asthma treatment with TSLP-directed drug AMG 104, the company’s outlook may improve in the long term. Despite strong performances from products like Evenity, Tavneos, and Lumakras, the current challenges and weak script trends prompt a neutral rating and a price target of $351 per share.

Amgen (AMGN) has been analyzed by 18 analysts, with a consensus rating of Hold. 11% of analysts recommend a Strong Buy, 17% recommend Buy, 67% suggest Holding, 6% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Amgen and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Amgen (AMGN) Forecast

Analysts have given Amgen (AMGN) a Hold based on their latest research and market trends.

According to 18 analysts, Amgen (AMGN) has a Hold consensus rating as of Jun 26, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $354.56, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $354.56, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Amgen (AMGN)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.